MINNEAPOLIS, Jan. 25, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its spatial biology brands, Lunaphore and Advanced Cell Diagnostics (ACD), will launch the first fully automated spatial multiomics workflow with same-section hyperplex detection of RNA and protein biomarkers.

明尼阿波利斯，2024年1月25日/PRNewswire/--Bio-Techne Corporation（NASDAQ:TECH）今天宣布，其空间生物学品牌Lunaphore和Advanced Cell Diagnostics（ACD）将推出第一个全自动空间多组学工作流程，该工作流程具有相同部分的RNA和蛋白质生物标志物的hyperplex检测。

This state-of-the-art solution revolutionizes the field of predictive biomarker research and drug development. The best-in-class multiomics solution leverages ACD's RNAscope™ HiPlex RNA detection and Lunaphore's universal multiplex sequential immunofluorescence (seqIF™) technology on the COMET™ platform, which performs protein detection with standard, non-conjugated antibodies.

这种最先进的解决方案彻底改变了预测性生物标志物研究和药物开发领域。一流的多组学解决方案利用ACD的RNAscope™ HiPlex RNA检测和Lunaphore的通用多重顺序免疫荧光（seqIF™) 彗星技术™ 平台，它使用标准的非偶联抗体进行蛋白质检测。

The multiomics application will be commercially available in Q2 2024..

multiomics应用程序将于2024年第二季度上市。。

Until now, researchers have faced challenges in integrating critical spatial information and accessing true multi-modal, same-cell analysis with full workflow automation. The Company's new multiomics solution for translational research overcomes this gap by enabling the correlation of RNA and protein data at the subcellular level in its spatial tissue context without any user intervention and with the highest throughput in the hyperplex market.

到目前为止，研究人员在整合关键空间信息和访问真正的多模式，同一细胞分析和全工作流自动化方面面临着挑战。该公司新的用于翻译研究的多组学解决方案通过在其空间组织环境中实现亚细胞水平的RNA和蛋白质数据的相关性而克服了这一差距，无需任何用户干预，并且在hyperplex市场上具有最高的吞吐量。

This fully automated workflow enables researchers and clinicians to generate highly robust data through reliable and reproducible target detection. It offers complete flexibility in panel design by selecting any protein target with the use of standard reagents, including clinically proven IHC antibodies and RNAscope..

这种全自动化的工作流程使研究人员和临床医生能够通过可靠且可重复的目标检测生成高度可靠的数据。它通过使用标准试剂（包括临床证明的IHC抗体和RNAscope）选择任何蛋白质靶标，在面板设计中提供了完全的灵活性。。

'Combining ACD's leading RNA detection technology with Lunaphore's fully automated high-throughput protein detection capabilities on the COMET system enables a best-in-class multiomics spatial biology solution,' commented Kim Kelderman, Bio-Techne's Chief Operating Officer. 'We remain focused on delivering breakthrough spatial technologies that empower researchers and clinicians to push boundaries in healthcare and ultimately improve patient outcomes.

Bio-Techne首席运营官Kim Kelderman评论道：“将ACD领先的RNA检测技术与Lunaphore在COMET系统上的全自动高通量蛋白质检测功能相结合，可以实现一流的多组学空间生物学解决方案。”我们仍然专注于提供突破性的空间技术，使研究人员和临床医生能够推动医疗保健的界限，并最终改善患者的预后。

With this cutting-edge application, we continue to lead the way and shape the future of the spatial biology market.'.

凭借这一尖端应用，我们将继续引领空间生物学市场的发展，并塑造其未来。”。

The complete multiomics solution will be showcased through a series of activities at the Lunaphore Suite, Curacao 4, at the Advances in Genome Biology and Technology (AGBT) 2024 General Meeting, taking place February 5-8, in Orlando, Florida. To book a meeting or find out more about Lunaphore and ACD's presence at the conference, please visit Lunaphore's website..

完整的多组学解决方案将通过2月5日至8日在佛罗里达州奥兰多举行的2024年基因组生物学与技术进步（AGBT）大会在库拉索岛的Lunaphore Suite上的一系列活动进行展示。要预订会议或了解更多有关Lunaphore和ACD出席会议的信息，请访问Lunaphore的网站。。

About Bio-TechneBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases.

关于Bio-TechneBio Techne Corporation（纳斯达克：TECH）是一家全球生命科学公司，为研究和临床诊断社区提供创新工具和生物活性试剂。Bio-Techne产品有助于对生物过程以及特定疾病的性质和进展进行科学研究。

They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated over $1.1 billion in net sales in fiscal 2023 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube..

它们有助于药物发现工作，并为准确的临床测试和诊断提供手段。Bio-Techne拥有数千种产品，2023财年净销售额超过11亿美元，在全球拥有约3100名员工。有关Bio-Techne及其品牌的更多信息，请访问https://www.bio-techne.com或者在社交媒体上关注该公司：Facebook、LinkedIn、Twitter或YouTube。。

About COMET™COMET™ is the only fully automated, high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies. COMET™ provides walk-away automation, integrating staining, imaging, and image preprocessing steps to obtain standard hyperplex images.

关于COMET™彗星™ 是唯一一个全自动，高通量，hyperplex平台，可确保可扩展性和可重复性，而无需结合一抗。彗星™ 提供步行自动化，集成染色，成像和图像预处理步骤以获得标准的hyperplex图像。

The multiomics capability of COMET™ enables the simultaneous analysis of both RNA and protein data within the spatial context of tissues to enhance the understanding of cellular dynamics and disease processes. COMET™ generates highly robust and reproducible data with full tissue preservation, allowing researchers to perform downstream modalities such as H&E or transcriptomics using the same slide.

COMET的多组学能力™ 能够在组织的空间背景下同时分析RNA和蛋白质数据，以增强对细胞动力学和疾病过程的理解。彗星™ 生成具有完整组织保存的高度稳健且可重复的数据，使研究人员能够使用相同的载玻片执行下游模式，例如H＆E或转录组学。

Its superior tissue profiling capabilities facilitate the analysis of 40 different spatial markers in each automated run on a tissue slide. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free primary antibodies, making panel design much more flexible and faster than any other hyperplex solution.

其优越的组织分析能力有助于在组织载玻片上的每次自动运行中分析40种不同的空间标记。与其他空间生物学解决方案相比，彗星™ 与现成的无标签初级抗体一起使用，使面板设计比任何其他hyperplex解决方案都更灵活，速度更快。

COMET™ works with regular glass slides from standard histology workflows; it is validated for human and mouse samples and is compatible with any other animal sample. The platform can be used for a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology.

彗星™ 使用标准组织学工作流程中的常规载玻片；它已针对人类和小鼠样品进行了验证，并与任何其他动物样品兼容。该平台可用于广泛的研究应用，从而大大提高了对疾病病理学的理解。

To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/.

了解更多有关彗星的信息™ 平台，请访问：https://lunaphore.com/products/comet/.

For further information on Lunaphore:Lindsey Rodger, Head of Communications[email protected]

有关Lunaphore的更多信息，请咨询通信主管林赛·罗杰（LindseyRodger）[受电子邮件保护]

Bio-Techne Corporation (NASDAQ: TECH)David Clair, Vice President, Investor Relations & Corporate Development[email protected]612-656-4416

Bio-Techne Corporation（NASDAQ:TECH）投资者关系与企业发展副总裁David Clair[受电子邮件保护]612-656-4416

SOURCE Bio-Techne Corporation

SOURCE Bio-Techne公司